BAP Officer Details
BAP Director of Education
Professor Hamish McAllister-Williams
Prof R. Hamish McAllister-Williams, BSc, MB,ChB, Ph.D., M.D., FRCPsych. is Professor of Affective Disorders in the Northern Centre for Mood Disorders at the Institute of Neuroscience, Newcastle University.
Prof McAllister-Williams qualified in medicine at Edinburgh, Scotland in 1987. Following house jobs he held a post as a Wellcome Trust Clinical Training Fellow in the Department of Pharmacology in Edinburgh gaining a PhD in Neuropharmacology for work studying serotonergic (5-HT) responses in central neurones. He subsequently undertook his initial clinical training in Psychiatry at the Royal Edinburgh Hospital and then moved to Newcastle in 1995 as a Clinical Lecturer. In 1999 he was awarded a UK Medical Research Council Clinician Scientist Fellowship at Senior Lecturer level to investigate the pathophysiology of affective disorders, in particular the role of serotonin and cortisol. He completed a research MD degree at Newcastle describing a novel method of exploring 5-HT function in man that has been used to study corticosteroid-5-HT interactions and 5-HT abnormalities in depressed patients. In 2004 he was appointed a Reader in Clinical Psychopharmacology and then Professor of Affective Disorders in 2017 at Newcastle University.
His research focuses on the pathophysiology and treatment of both bipolar and unipolar affective disorders. He works clinically in the tertiary level specialist Regional Affective Disorders Service in Northumberland Tyne and Wear NHS Foundation Trust, providing outpatient and inpatient services for patients with treatment refractory mood disorders. He is a past General Secretary of the British Association for Psychopharmacology (BAP) and was appointed in 2012 as the BAP Director of Education. He is a major contributor to their CPD programme. He has published in excess of 150 journal papers, reviews, book chapters and conference abstracts.
Declaration of Interests
- Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
- Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
- Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
- Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
- Janssen, LivaNova, Lundbeck, P1Vital, Sage Therapeutics, Syntropharma
- Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
- Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
- Eli Lilly
- Have you, in the past three years, had membership of the speakers' bureau for any company?
- Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
- Janssen, LivaNova, Lundbeck, Magstim, OM Pharma, Pfizer, Sunovion, Wiley
- Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
- Have you, in the past three years, recruited patients for industry-sponsored studies?
- COMPASS Pathways: trial of psilocybin for depression, LivaNova
- If there is anything else you feel it necessary to disclose, please provide details below:
Form completed on 23rd July 2019